Search Results Search Sort by RelevanceMost Recent Podcast Jul 2024 Author Interview: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?” Dr Katherin M. Duthie joins Ethics Talk to discuss her article, coauthored with Dr Kathryn A. Dong: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?” Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551. Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512. Viewpoint Jul 2024 Opioid Epidemic Grief and Characterological Harm Reduction Christy A. Rentmeester, PhD Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale. AMA J Ethics. 2024;26(7):E587-590. doi: 10.1001/amajethics.2024.587. History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024;26(7):E580-586. doi: 10.1001/amajethics.2024.580. Pagination First page « First Previous page ‹ Previous … Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Current page 16
Podcast Jul 2024 Author Interview: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?” Dr Katherin M. Duthie joins Ethics Talk to discuss her article, coauthored with Dr Kathryn A. Dong: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?”
Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551.
Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512.
Viewpoint Jul 2024 Opioid Epidemic Grief and Characterological Harm Reduction Christy A. Rentmeester, PhD Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale. AMA J Ethics. 2024;26(7):E587-590. doi: 10.1001/amajethics.2024.587.
History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024;26(7):E580-586. doi: 10.1001/amajethics.2024.580.